Agios Pharmaceuticals Set to Present at Major Healthcare Conference
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a frontrunner in cellular metabolism and PK activation, is excited to announce that its management team will be presenting at the upcoming TD Cowen 45th Annual Healthcare Conference. This key event will take place on a Monday in early March at 10:30 a.m. ET. Investors and stakeholders are encouraged to tune in to the live webcast available on the Investors section of the company's website.
Details of the Presentation
The presentation will delve into Agios' innovative approaches and recent advancements in treating rare diseases. Following the live session, a replay will be accessible for at least two weeks, allowing those unable to attend in real time to catch up on the insights shared by the management team.
About Agios Pharmaceuticals
As a pioneering leader in PK activation, Agios is dedicated to developing transformative therapies aimed at improving the lives of patients dealing with rare diseases. The company currently markets a first-in-class pyruvate kinase (PK) activator designed for adults suffering from PK deficiency. This is particularly significant as it marks the first disease-modifying therapy for this debilitating condition, which leads to lifelong and severe anemia.
Innovative Therapeutics Pipeline
Agios is continuously pushing the boundaries of science with its robust pipeline of investigational medicines. Their research focuses on several programs, including treatments for alpha- and beta-thalassemia, sickle cell disease, and myelodysplastic syndromes (MDS)-associated anemia. Additionally, they are exploring a preclinical TMPRSS6 siRNA candidate aimed at polycythemia vera, which further exemplifies their commitment to tackling diverse hematologic disorders.
Company Mission and Values
At the core of Agios Pharmaceuticals' mission is the commitment to delivering cutting-edge therapies and improving patients' quality of life. Their deep scientific expertise coupled with a keen understanding of cellular metabolism positions them as a leader in the field, not just in terms of existing treatments but also in paving the way for future innovations.
Future Directions
With a solid foundation in classical hematology and an ambitious pipeline, Agios aims to continue its trajectory of growth and leadership in rare disease therapeutics. The company's ongoing trials and research initiatives represent significant steps towards comprehensive treatment options for patients globally. Their focus remains steadfast on patient outcomes and scientific excellence, aiming for transformative impacts in medical care for rare conditions.
Contact Information
For further inquiries or details about Agios Pharmaceuticals, interested parties are encouraged to reach out to the company's investor relations team:
Investor Contact:
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
Email: IR@agios.com
Media Contact:
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Email: Media@agios.com
Frequently Asked Questions
What is the focus of Agios Pharmaceuticals?
Agios Pharmaceuticals specializes in cellular metabolism and PK activation, developing therapies aimed at rare diseases.
When will Agios present at the TD Cowen Healthcare Conference?
Agios will present at the conference on a Monday in early March at 10:30 a.m. ET.
What is Agios' most notable product?
Agios markets a first-in-class PK activator for adults with PK deficiency, which is a significant breakthrough in rare disease treatment.
How can I access the webcast of the presentation?
The live webcast will be available on Agios' website in the Investors section, along with a replay for later viewing.
Who can I contact for more information about Agios?
For more information, you can contact Chris Taylor for investor relations or Eamonn Nolan for media inquiries through the provided email addresses.
